Analysts Keeping an Eye on Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

The shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX)currently has mean rating of 2.9 while 2 analyst have recommended the shares as ‘BUY’ ,3 recommended as ‘OUTPERFORM’ and 10 recommended as ‘HOLD’.The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell

The mean price target for the shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX)is at $51.89 while the highest price target suggested by the analysts is $175.00 and low price target is $11.00. The mean price target is calculated keeping in view the consensus of 18 brokerage firms.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 2.56B by 14 analysts. The means estimate of sales for the year ending Dec 16 is 10.25B by 20 analysts.

The average estimate of EPS for the current fiscal quarter for Valeant Pharmaceuticals Intl Inc (NYSE:VRX)stands at $1.73 while the EPS for the current year is fixed at $7.14 by 18.00 analysts

The next one year’s EPS estimate is set at 8.30 by 18.00 analysts while a year ago the analysts suggested the company’s EPS at $7.14. The analysts also projected the company’s long-term growth at 9.60% for the upcoming five years

In its latest quarter ended on 31 Mar 2016 , Valeant Pharmaceuticals Intl Inc (NYSE:VRX)reported earnings of $1.27. The posted earnings missed the analyst’s consensus by $-0.10 with the surprise factor of -7.30%. In the matter of earnings surprises, the term ‘Cockroach Effect’ is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) traded up +6.52% during trading on Friday, hitting $25.50 . The stock had a trading volume of 41.6 M shares. The firm has a 50 day moving average of $29.63 and a 200-day moving average of $63.43. The stock has a market cap of $8.74B. On Aug 6, 2015 the shares registered one year high at $263.81 and the one year low was seen on Jun 7, 2016.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on June 9, 2016  announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the Dermatologic and Ophthalmic Drugs Advisory Committee will review Valeant’s New Drug Application (NDA) for brodalumab on July 19, 2016.

On January 25, 2016, Valeant announced that the FDA had accepted for review the Biologics License Application (BLA) submitted by AstraZeneca (LSE/SSE/NYSE: AZN) in partnership with Valeant for brodalumab injection, 210 mg, a monoclonal antibody that targets the IL-17 receptor, in development for patients with moderate to severe plaque psoriasis. The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of November 16, 2016.

“Plaque psoriasis is a chronic disease of the immune system that can impair many aspects of patients’ lives,” said Joseph C. Papa, chairman and chief executive officer.  “We look forward to the opportunity to discuss brodalumab treatment options for adult patients with moderate to severe plaque psoriasis and provide information about this novel antibody we are developing.”

As previously announced, the Marketing Authorisation Application (MAA) for brodalumab in psoriasis was accepted by the European Medicines Agency (EMA) in Q42015.  In October, 2015, Valeant entered into a collaboration agreement with AstraZeneca under which Valeant has an exclusive license to develop and commercialise brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co., Ltd.